Probiotics And Ozonated Olive Oil To Maintain Oral Eubiosis In Stage I And II Periodontitis Patients

NCT ID: NCT06955546

Last Updated: 2025-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-07

Study Completion Date

2024-07-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to investigate the clinical benefits of the combined use of ozonized olive oil products (mouthwash and toothpaste) and probiotics on the health status of patients with Stage I and II periodontitis; could include any of the following:

* Male or female, aged between 18 and 70 years of any race.
* Diagnosis of stage I or II periodontitis according to the American Academy of Periodontology and the European Federation of Periodontology 2017 classification of periodontal diseases.
* Good general health.
* Ability to understand and comprehend the study's instructions and sign the informed consent.

The main question it aims to answer is: the single or combined use of ozonized olive oil products (mouthwash and toothpaste) and probiotics could improve the oral health status of patients with Stage I and II periodontitis compared to placebo?

Participants will proceed to their daily domiciliar oral hygiene maneuvers with the products given by investigators. The toothpaste was used twice daily, morning and evening, followed by rinsing with undiluted mouthwash for one minute. After rinsing, the patient did not rinse further with water and refrained from eating, drinking, and smoking for at least one hour. Domiciliary mechanical and drug therapies were continued, without modification, for 30 days. Moreover, the patients received a probiotic tablet daily.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Disease Periodontal Disease Stage 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

3 parallel arms interventional study model
Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: Placebo Group

In this group the patients received a placebo toothpaste, mouthwash and probiotics. Their appearance was kept identical to mimic the real products containing effective substances, in order to dissuade the patient to drop out.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Patients received a placebo toothpaste, mouthwash and probiotics. Their appearance was kept identical to mimic the real products containing effective substances, in order to dissuade the patient to drop out.

Group B: effective toothpaste and mouthwash. Placebo probiotics

The patients of this group received effective toothpaste and mouthwash. Probiotics tablets were placebo.

Group Type EXPERIMENTAL

Toothpaste Product

Intervention Type DRUG

Patients have to use the Curasept Prevent Toothpaste daily, during their domiciliar oral hygiene maneuvers.

Link at: https://curaseptspa.it/prodotti/curasept-prevent-dentifricio/

Mouthwash Product

Intervention Type DRUG

Patients have to use the Curasept Prevent Mouthwash daily, during their domiciliar oral hygiene maneuvers.

Link at: https://curaseptspa.it/prodotti/curasept-prevent-collutorio/

Group C: effective toothpaste, mouthwash and probiotics.

The patients of this group received effective toothpaste, mouthwash and probiotics.

Group Type EXPERIMENTAL

Toothpaste Product

Intervention Type DRUG

Patients have to use the Curasept Prevent Toothpaste daily, during their domiciliar oral hygiene maneuvers.

Link at: https://curaseptspa.it/prodotti/curasept-prevent-dentifricio/

Mouthwash Product

Intervention Type DRUG

Patients have to use the Curasept Prevent Mouthwash daily, during their domiciliar oral hygiene maneuvers.

Link at: https://curaseptspa.it/prodotti/curasept-prevent-collutorio/

Probiotic

Intervention Type DIETARY_SUPPLEMENT

Patients received a daily tablet of Curasept Prevent Probiotics. Link at: https://curaseptspa.it/prodotti/curasept-prevent-probiotico-integratore-alimentare/

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Toothpaste Product

Patients have to use the Curasept Prevent Toothpaste daily, during their domiciliar oral hygiene maneuvers.

Link at: https://curaseptspa.it/prodotti/curasept-prevent-dentifricio/

Intervention Type DRUG

Mouthwash Product

Patients have to use the Curasept Prevent Mouthwash daily, during their domiciliar oral hygiene maneuvers.

Link at: https://curaseptspa.it/prodotti/curasept-prevent-collutorio/

Intervention Type DRUG

Probiotic

Patients received a daily tablet of Curasept Prevent Probiotics. Link at: https://curaseptspa.it/prodotti/curasept-prevent-probiotico-integratore-alimentare/

Intervention Type DIETARY_SUPPLEMENT

Placebo

Patients received a placebo toothpaste, mouthwash and probiotics. Their appearance was kept identical to mimic the real products containing effective substances, in order to dissuade the patient to drop out.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Curasept Prevent Toothpaste Curasept Prevent Mouthwash Curasept Prevent Probiotic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, aged between 18 and 70 years of any race.
* Diagnosis of stage I or II periodontitis according to the American Academy of Periodontology and the European Federation of Periodontology 2017 classification of periodontal diseases.
* Good general health.
* Ability to understand and comprehend the study's instructions and sign the informed consent.

Exclusion Criteria

* Pregnancy and breastfeeding.
* Periodontal or antibiotic therapy in the last two months.
* Systemic diseases that could influence the severity of periodontal disease or therapeutic success (e.g., Down syndrome, HIV, Diabetes Mellitus).
* Smoking \> 10 cigarettes per day.
* Need for antibiotic prophylaxis for dental procedures.
* Chronic use of anti-inflammatory drugs, calcium channel blockers, antidepressants, and anticonvulsants.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Massimo Corsalini

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Massimo Corsalini

Associate Professor

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari

Bari, BA, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Prot. 1983/CEL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.